Tüberküloz ile Mücadelede Covıd-19’un Etkisi

Yıl 2023, , 246 - 257, 31.05.2023

Murat Avcı , Pınar Etiz

https://doi.org/10.52369/togusagbilderg.1153234

Öz

Zoonotik koronavirüs ailesine ait olan SARS-CoV-2’nin neden olduğu COVID-19 pandemisi çok sayıdaki ülkeyi ekonomik, siyasal ve sosyal açıdan olumsuz etkilemektedir. Bu durum ülkelerin sağlık sistemleri üzerinde ciddi bir yük oluşturmaktadır. Birçok ülkede personel sıkıntısı ve yoğun bakım yetersizliği yaşanmıştır. Bunların dışında maske ve solunum cihazı gibi ihtiyaç duyulan malzemeler konusunda sorunlar ortaya çıkmış ve çeşitli tıbbi müdahaleler ile özellikle kronik/bulaşıcı hastalıkların teşhis ve tedavisinde aksamalar meydana gelmiştir. COVID-19 pandemisi nedeniyle uygulanan sokağa çıkma yasağı ve sağlık sistemleri kaynaklarının COVID-19 ile mücadeleye aktarılmasından dolayı yeni hasta teşhisinin veya mevcut hasta tedavisinin olumsuz etkilendiği hastalıklardan biride Tüberküloz hastalığıdır. Tüberküloz, COVID-19 hastalığından önceki dönemde, tek bir bulaşıcı ajandan kaynaklanan tüm bulaşıcı hastalıklar arasında en yüksek ölüm nedenlerinden biri olarak ilk sırada yer almaktaydı. COVID-19 hastalığı, Tüberkülozu tahtından etmiştir. COVID-19 pandemisi koşullarından dolayı Tüberküloz ile mücadele için hazırlanan programlarda aksamanın olması önümüzdeki yıllarda Tüberküloz vaka sayısında artış beklentisini güçlendirmektedir. Tüberküloz vaka sayısında meydana gelebilecek artışlar, ülkeleri, yeniden alevlenen bir sorunla karşı karşıya bırakabilir. Bu derlemenin amacı, COVID-19’un Tüberküloz üzerindeki olumsuz etkisini örneklerle göstermek ve ileride yaşanabilecek pandemi süreçleri için bulaşıcı hastalıklarla mücadele konusunda çözüm önerilerinde bulunarak literatüre katkı sağlamaktır.

Anahtar Kelimeler

Bulaşıcı hastalıklar, COVID-19, Pandemi, SARS-CoV-2, Tüberküloz

Kaynakça

• 1. Chopra KK, Arora VK, Singh S. COVID 19 and tuberculosis. Indian J Tuberc. 2020;67(2):149–51.
• 2. Gopalaswamy R, Subbian S. Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis. Int J Mol Sci. 2021;22(7):3773.
• 3. Lai CC, Yu WL. The COVID-19 pandemic and tuberculosis in Taiwan. J Infect. 2020;81(2):e159–61.
• 4. Matatiele M, Stiegler N, Bouchard JP. Tri-infection: Tuberculosis, HIV, COVID-19 and the already strained South African health system. Brain Behav Immun. 2021;96:5–6.
• 5. Migliori GB, Tiberi S, García-Basteiro AL, Duarte R. Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021. Pulmonology. 2021;27(2):94–6.
• 6. Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules. 2020;26(1):39.
• 7. Pathak S, Jolly MK, Nandi D. Countries with high deaths due to flu and tuberculosis demonstrate lower COVID-19 mortality: roles of vaccinations. Hum Vaccines Immunother. 2021;17(9):2851–62.
• 8. Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID‐19: Virology, biology and novel laboratory diagnosis. J Gene Med. 2021;23(2):e3303.
• 9. Shi Y, Wang G, Cai X peng, Deng J wen, Zheng L, Zhu H hong, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5):343–60.
• 10. Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H, et al. Coronavirus disease 2019 (COVID‐19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2020;e12998.
• 11. Vakili S, Savardashtaki A, Jamalnia S, Tabrizi R, Nematollahi MH, Jafarinia M, et al. Laboratory Findings of COVID-19 Infection are Conflicting in Different Age Groups and Pregnant Women: A Literature Review. Arch Med Res. 2020;51(7):603–7.
• 12. Suárez I, Fünger SM, Kröger S, Rademacher J, Fätkenheuer G, Rybniker J. The Diagnosis and Treatment of Tuberculosis. Dtsch Arzteblatt Int. 2019;116(43):729–35.
• 13. Acharya B, Acharya A, Gautam S, Ghimire SP, Mishra G, Parajuli N, et al. Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis. Mol Biol Rep. 2020;47(5):4065–75.
• 14. Machado D, Couto I, Viveiros M. Advances in the molecular diagnosis of tuberculosis: From probes to genomes. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2019;72:93–112.
• 15. Rieder HL. Air pollution, COVID-19, and tuberculosis interrelationship. Indian J Tuberc. 2020;67(3):281–3.
• 16. Saktiawati AMI, Putera DD, Setyawan A, Mahendradhata Y, van der Werf TS. Diagnosis of tuberculosis through breath test: A systematic review. EBioMedicine. 2019;46:202–14.
• 17. Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2015;32:87–93.
• 18. Udwadia ZF, Vora A, Tripathi AR, Malu KN, Lange C, Sara Raju R. COVID-19 -Tuberculosis interactions: When dark forces collide. Indian J Tuberc. 2020;67(4):S155–62.
• 19. Visca D, Ong CWM, Tiberi S, Centis R, D’Ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology. 2021;27(2):151–65.
• 20. MacLean E, Kohli M, Weber SF, Suresh A, Schumacher SG, Denkinger CM, et al. Advances in Molecular Diagnosis of Tuberculosis. J Clin Microbiol. 2020;58(10):e01582-19.
• 21. Ramos-Sono D, Laureano R, Rueda D, Gilman RH, La Rosa A, Ruiz J, et al. An electrochemical biosensor for the detection of Mycobacterium tuberculosis DNA from sputum and urine samples. PloS One. 2020;15(10):e0241067.
• 22. Gardner BJ, Kilpatrick AM. Contact tracing efficiency, transmission heterogeneity, and accelerating COVID-19 epidemics. PLoS Comput Biol. 2021;17(6):e1009122.
• 23. Kim W, Lee H, Chung YD. Safe contact tracing for COVID-19: A method without privacy breach using functional encryption techniques based-on spatio-temporal trajectory data. PLoS ONE. 2020;15(12):e0242758.
• 24. Whitelaw S, Mamas MA, Topol E, Van Spall HGC. Applications of digital technology in COVID-19 pandemic planning and response. Lancet Digit Health. 2020;2(8):e435–40.
• 25. Aznar ML, Espinosa-Pereiro J, Saborit N, Jové N, Sánchez Martinez F, Pérez-Recio S, et al. Impact of the COVID-19 pandemic on tuberculosis management in Spain. Int J Infect Dis. 2021;108:300–5.
• 26. Fuady A, Houweling TAJ, Richardus JH. COVID-19 and Tuberculosis-Related Catastrophic Costs. Am J Trop Med Hyg. 2021;104(2):436–40.
• 27. Joffe AR. COVID-19: Rethinking the Lockdown Groupthink. Front Public Health. 2021;9:625778.
• 28. Singh R, Kang A, Luo X, Jeyanathan M, Gillgrass A, Afkhami S, et al. COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development. FASEB J. 2021;35(3):e21409.
• 29. Talevi D, Socci V, Carai M, Carnaghi G, Faleri S, Trebbi E, et al. Mental health outcomes of the CoViD-19 pandemic. Riv Psichiatr. 2020;55(3):137–44.
• 30. Duarte R, Aguiar A, Pinto M, Furtado I, Tiberi S, Lönnroth K, et al. Different disease, same challenges: Social determinants of tuberculosis and COVID-19. Pulmonology. 2021;27(4):338–44.
• 31. World Health Organization. Global Tuberculosis Report 2021 [Internet]. 2021 [son güncelleme tarihi Ekim 2021; 12 Haziran 2022 tarihinde erişildi]. Erişim adresi: https://www.who.int/teams/global-tuberculosis-programme/tb-reports
• 32. World Health Organization. Coronavirus disease (COVID-19) [İnternet]. 2022 [son güncelleme tarihi Temmuz 2022; 01 Ağustos 2022 tarihinde erişildi]. Erişim adresi: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
• 33. Crisan-Dabija R, Grigorescu C, Pavel CA, Artene B, Popa IV, Cernomaz A, et al. Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes. Can Respir J. 2020 Sep 5;2020:1401053.
• 34. Riou C, du Bruyn E, Stek C, Daroowala R, Goliath RT, Abrahams F, et al. Relationship of SARS-CoV-2–specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. J Clin Invest. 2021;131(12):e149125.
• 35. Saunders MJ, Evans CA. COVID-19, tuberculosis and poverty: preventing a perfect storm. Eur Respir J. 2020;56(1):2001348.
• 36. Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Tuberculosis Control in Jiangsu Province, China. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021 Aug 2;73(3):542–4.
• 37. Kwak N, Hwang SS, Yim JJ. Effect of COVID-19 on Tuberculosis Notification, South Korea. Emerg Infect Dis. 2020;26(10):2506–8.
• 38. Magro P, Formenti B, Marchese V, Gulletta M, Tomasoni LR, Caligaris S, et al. Impact of the SARS-CoV-2 epidemic on tuberculosis treatment outcome in Northern Italy. Eur Respir J. 2020;56(4):2002665.
• 39. UK Health Security Agency. Tuberculosis in England: 2021 report [Internet]. 2022 [son güncelleme tarihi Mart 2022; 18 Haziran 2022 tarihinde erişildi]. Erişim adresi: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1064395/TB_annual-report-2021.pdf
• 40. Kargarpour Kamakoli M, Hadifar S, Khanipour S, Farmanfarmaei G, Fateh A, Mostafaei S, et al. Tuberculosis under the Influence of COVID-19 Lockdowns: Lessons from Tehran, Iran. mSphere. 2021 Feb 24;6(1):e00076-21.
• 41. Jain VK, Iyengar KP, Samy DA, Vaishya R. Tuberculosis in the era of COVID-19 in India. Diabetes Metab Syndr. 2020;14(5):1439–43.
• 42. Iyengar KP, Jain VK. Tuberculosis and COVID-19 in India- double trouble! Indian J Tuberc. 2020;67(4):S175–6.
• 43. Falzon D, den Boon S, Kanchar A, Zignol M, Migliori GB, Kasaeva T. Global reporting on tuberculosis preventive treatment among contacts. Eur Respir J. 2022;59(3):2102753.
• 44. Jeremiah C, Petersen E, Nantanda R, Mungai BN, Migliori GB, Amanullah F, et al. The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to End TB. Int J Infect Dis [Internet]. 2022 [son güncelleme tarihi Mart 2022; 18 Haziran 2022 tarihinde erişildi]; Erişim adresi: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934249/
• 45. Pai M, Kasaeva T, Swaminathan S. Covid-19’s Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. 2022;386(16):1490–3.